https://www.youtube.com/shorts/72mlT-K3WLo

We're proud to support Clarified Precision Medicine and their CTO, Daniel Rotroff, through our Reshape Health Grants at Arionkoder.
Clarified is working at the frontier of cancer treatment—using AI and Deep Learning to personalize care based on a patient's unique molecular tumor profile.
Together, we’re:
🔹 Designing a treatment data dashboard that translates complex datasets into actionable insights.
🔹 Leveraging AI models to analyze batch data from healthcare and pharma sources, highlighting what works—and what doesn’t.
Follow their journey as they help bring precision oncology to the forefront.

See the video transcript below:

My name is Daniel Rotroff, and I'm the Chief Technology Officer for Clarified Precision Medicine. So Clarified Precision Medicine aims to make sure that all cancer patients receive the right therapy for them at the right time during their course of treatment.

So I think one of the things that we've needed really is we've accumulated quite a lot of data, and this data can help us gain insights into the clinical practices that we're working with. And they can also help us understand some of the gaps that exist either within a certain cancer type or across cancer types. And that's where we wanted to work with Arionkoder to develop tools to help us, you know, really take a deeper insight into the data that we've collected, identify things like how often patients are switching therapies based on the results of their sequencing result.

Right now, there's a a big need. There's still significant gaps despite the therapies that are available, the science and research supporting it. There's still, you know, gaps in implementation, and I think the best things we can do together help to highlight those gaps and see if we could develop solutions to them, to make sure that, you know, we can help meet the needs of patients. 

I think those things will those insights that we can help, because, ultimately, we'll wanna work with those groups as well to sort of help close all these gaps. So I think, you know, we will our success is gonna be measured by how we can reach more patients and make sure that they get on the right therapies.